Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-17
2008-12-30
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000, C544S223000, C544S220000, C544S182000
Reexamination Certificate
active
07470688
ABSTRACT:
A compound of the formula (I):wherein:A and B together represent an optionally substituted, fused aromatic ring;D is selected from:(i)where Y1is selected from CH and N, Y2is selected from CH and N, Y3is selected from CH, CF and N; and(ii)where Q is O or S;RDis:whereinRN1is selected from H and optionally substituted C1-10alkyl;X is selected from a single bond, NRN2, CRC3RC4and C═O;RN2is selected from H and optionally substituted C1-10alkyl;RC3and RC4are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10alkyl, optionally substituted C5-20aryl or optionally substituted C3-20heterocyclyl;Y is selected from NRN3and CRC1RC2;RC1and RC2are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10alkyl, optionally substituted C5-20aryl or optionally substituted C3-20heterocyclyl; RC1and RC2together with the carbon atom to which they are attached may forman optionally substituted spiro-fused C5-7carbocylic or heterocyclic ring; andwhen X is a single bond RN1and RC2may together with the N and C atoms to which they are bound, form an optionally substituted C5-7heterocyclic ring;and when X is CRC3RC4, RC2and RC4may together form an additional bond, such that there is a double bond between the atoms substituted by RC1and RC3.
REFERENCES:
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 4841047 (1989-06-01), Engel et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5556856 (1996-09-01), Engel et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5874444 (1999-02-01), West
patent: 5886178 (1999-03-01), Allen et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6340684 (2002-01-01), Napoletano et al.
patent: 6426415 (2002-07-01), Jackson et al.
patent: 6476048 (2002-11-01), Szabo et al.
patent: 6498160 (2002-12-01), Napoletano et al.
patent: 6514983 (2003-02-01), Li
patent: 6514984 (2003-02-01), Watanabe
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6677333 (2004-01-01), Seko et al.
patent: 2002/0183325 (2002-12-01), Martin et al.
patent: 2004/0023968 (2004-02-01), Martin et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0080096 (2005-04-01), Ishida et al.
patent: 2005/0227919 (2005-10-01), Kudos
patent: 2006/0063767 (2006-03-01), Javaid et al.
patent: 2006/0142293 (2006-06-01), Martin et al.
patent: 2008/0146575 (2008-06-01), Menear et al.
patent: 2143745 (1973-03-01), None
patent: 3813531 (1988-04-01), None
patent: 287 032 (1991-02-01), None
patent: 0030861 (1981-06-01), None
patent: 0269968 (1988-06-01), None
patent: 0355750 (1990-02-01), None
patent: 0389995 (1990-10-01), None
patent: 0502575 (1992-09-01), None
patent: 0590551 (1994-04-01), None
patent: 0634404 (1995-01-01), None
patent: 0699754 (1996-03-01), None
patent: 0705903 (1996-04-01), None
patent: 0792643 (1997-09-01), None
patent: 2262513 (1975-09-01), None
patent: 721286 (1955-01-01), None
patent: 2384776 (2004-03-01), None
patent: MI98A001671 (1999-04-01), None
patent: 54156526 (1979-12-01), None
patent: 58164577 (1983-09-01), None
patent: 62-252774 (1987-11-01), None
patent: WO 91/18591 (1991-12-01), None
patent: WO 93/14086 (1993-07-01), None
patent: WO 94/10151 (1994-05-01), None
patent: WO 95/24379 (1995-09-01), None
patent: WO 96/19225 (1996-06-01), None
patent: WO 98/43477 (1998-10-01), None
patent: WO 98/51308 (1998-11-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/44612 (1999-09-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 00/05219 (2000-02-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/67734 (2000-11-01), None
patent: WO 01/12199 (2001-02-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16137 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/23390 (2001-04-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 01/85686 (2001-11-01), None
patent: WO 01/85687 (2001-11-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/90077 (2001-11-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 03/070726 (2002-05-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/007959 (2003-01-01), None
patent: WO 03/051879 (2003-06-01), None
patent: WO 03/055865 (2003-07-01), None
patent: WO 03/057145 (2003-07-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03/070707 (2003-08-01), None
patent: WO 03/080581 (2003-10-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/080976 (2004-09-01), None
patent: WO 2005/053662 (2005-06-01), None
Szabo, J. Thoracic & Cardiovasc. Surg. 2003, 126, 651-8.
Bloch, et al., J. Thoracic & Cardiovascular Surg, vol. 128, No. 2, 323-324.
Miller, Brit. J. Pharm. 2004, 143, 515-516.
Cuzzocrea, Pharmacolog. Res., 52 (2005) 72-82.
Cockraft, et al., Bioorg. Med. Chem. Lett. 16(2006) 1040-1044.
Tasatargil, et al., Pharmacology 2004: 72; 99-105.
Affar, E. B. et al.,Anal. Biochem., 1998, vol. 259, No. 2, 280-3.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.”Archives of toxicology, Supplement.Archiv fur Toxikologie. Supplement, vol. 7, 219-231 (1984).
Ame et al.,J. Biol. Chem., 1999, vol. 274, 17860-17868.
Ame , Bioessays (2004) 26(8):882-893.
Angell et al.,EMBO J., 1997, vol. 16, No. 12, 3675-3684.
Arnaudeau, C. et al.,J. Mol. Biol, 2001, vol. 307, 1235-45.
Banasik, M. et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferse”,J. Biol. Chem., 1992, vol. 267, 1569-1575.
Banasik, M. et al.,Mol. Cell Biochem., 1994, vol. 138, 185-197.
Ben-Hur et al., 1984,British Journal of Cancer, 49 (Suppl. VI): 39-42.
Berge et al., 1977, “Pharmaceutically Acceptable Salts,”J. Pharm. Sci., vol. 66, 1-19. Protective Groups in Organic Synthesis (T. Green and P. Wuts, Wiley, 1991).
Berger, N. A. et al., “Poly (ADP-ribose) in cellular response to DNA damage”,Radiation Research, 1985, vol. 101, 4-14.
Bhattacharyya, A. et al.,J. Biol. Chem., 2000, vol. 275, 23899-903.
Bold et. al.,J. Med. Chem., 2000, 43, 3200.
Bold, G. et al., “New anilinophthalazines as potent and orally well absorbed inhibitors of the FEBF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis”,J. Med. Chem., 2000, vol. 43, No. 12, 2310-2323.
Bowman et al., “Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro,”British Journal of Cancer, vol. 84(1), 106-112 (2001).
Brummelkamp, T. R. et al.,Science, 2002, vol. 296, 550-553.
Bundgaard, H.,Design of Prodrugs, 1 (1985) Elsevier Science Publishers.
Burzio, L. et al., “Poly (adenosine diphosphoribose) synthase activity of isolated nuclei of normal and leukemic leukocytes (38930)”,Proc. Soc. Exp. Bio. Med., 1975, vol. 149, 933-938.
Calabrese, Clin. Cancer Res. (2003) 9:2711-2718.
Caldecott, Cell (2003) 112:7-10.
Cantoni, O. et al., “Hydrogen peroxide insult in cultured mammalian cells: relationships between DNA single-strand breakage, poly (ADP-ribose) metabolism and cell killing”,Biochim. Biophys. Acta, 1989, vol. 1014, 1-7.
Catteau, A. et al.,Oncogene, 1999, vol. 18, 1957-65.
Chappuis, P. O. et al.,Cancer Treat. Res., 2002, vol. 107, 29-59.
Chalmers, Clin. Oncol. (2004) 16(1):29-39.
Chiarugi, Trends Pharmacol. Sci. (2002) 23:122-129.
Cosi, C. et al., “Poly (ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells”,J.Neurosci. Res., 1994, vol. 39, 38-46.
Cosi, C., “New inhibitors of poly(
Barr Martin Niall Morrison
Cockcroft Xiao-Ling Fan
Gomez Sylvie
Hummersone Marc Geoffrey
Javaid Muhammad Hashim
Berch Mark L.
Jaisle Cecilia M
Maybridge Limited
Michael & Best & Friedrich LLP
LandOfFree
Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4040498